Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TransImmune: Encapsulated Fecal Microbiota Transfer in Cirrhosis with Ascites
2023-507790-18-00Phase 2Authorised
- Sponsor
- University Hospital RWTH Aachen
- Start
- Aug 2024
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Cirrhosis and ascites comparing INTESTIFIX 001 with Intestifix 001 placebo (2 arms). Primary endpoints: Serious adverse events and Treatment-emergent adverse events and adverse events. Planned start Aug 2024; status: authorised.
02
Drugs
INTESTIFIX 001
03
Conditions
Cirrhosisascites
Beyond the preview
Go deeper on 2023-507790-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507790-18-00.